Targeted Agents and Immunotherapies: Optimizing Outcomes in Melanoma

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2017 Apr 5

PMID 28374786

Citations 616

Authors

Jason J Luke

Keith T Flaherty

Antoni Ribas

Georgina V Long

Affiliations

Soon will be listed here.

Abstract

Treatment options for patients with metastatic melanoma, and especially BRAF-mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of eight new therapeutic agents. During this period, the treatment paradigm for BRAF-mutant disease has evolved rapidly: the standard-of-care BRAF-targeted approach has shifted from single-agent BRAF inhibition to combination therapy with a BRAF and a MEK inhibitor. Concurrently, immunotherapy has transitioned from cytokine-based treatment to antibody-mediated blockade of the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and, now, the programmed cell-death protein 1 (PD-1) immune checkpoints. These changes in the treatment landscape have dramatically improved patient outcomes, with the median overall survival of patients with advanced-stage melanoma increasing from approximately 9 months before 2011 to at least 2 years - and probably longer for those with BRAF-V600-mutant disease. Herein, we review the clinical trial data that established the standard-of-care treatment approaches for advanced-stage melanoma. Mechanisms of resistance and biomarkers of response to BRAF-targeted treatments and immunotherapies are discussed, and the contrasting clinical benefits and limitations of these therapies are explored. We summarize the state of the field and outline a rational approach to frontline-treatment selection for each individual patient with BRAF-mutant melanoma.

Citing Articles

Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma.

Kuras M, Betancourt L, Hong R, Szadai L, Rodriguez J, Horvatovich P Cancers (Basel). 2025; 17(5).

PMID: 40075679 PMC: 11899103. DOI: 10.3390/cancers17050832.

Bioinformatics analysis reveals novel tumor antigens and immune subtypes of skin cutaneous melanoma contributing to mRNA vaccine development.

Yang R, He J, Kang D, Chen Y, Huang J, Li J Front Immunol. 2025; 16:1520505.

PMID: 40066453 PMC: 11891200. DOI: 10.3389/fimmu.2025.1520505.

FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma.

Lubrano S, Cervantes-Villagrana R, Faraji F, Ramirez S, Sato K, Adame-Garcia S Cancer Cell. 2025; 43(3):428-445.e6.

PMID: 40020669 PMC: 11903146. DOI: 10.1016/j.ccell.2025.02.001.

High-Glucose-Induced Metabolic and Redox Alterations Are Distinctly Modulated by Various Antidiabetic Agents and Interventions Against FABP5/7, MITF and ANGPTL4 in Melanoma A375 Cells.

Nishikiori N, Ohguro H, Watanabe M, Higashide M, Ogawa T, Furuhashi M Int J Mol Sci. 2025; 26(3).

PMID: 39940783 PMC: 11817646. DOI: 10.3390/ijms26031014.

Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma.

Tompkins A, Gray Z, Dadey R, Zenkin S, Batavani N, Newman S J Immunother Cancer. 2025; 13(2).

PMID: 39939139 PMC: 11822426. DOI: 10.1136/jitc-2024-009568.

References

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D . Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2014; 372(1):30-9. DOI: 10.1056/NEJMoa1412690. View

Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

Curran M, Montalvo W, Yagita H, Allison J . PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010; 107(9):4275-80. PMC: 2840093. DOI: 10.1073/pnas.0915174107. View

Gray E, Rizos H, Reid A, Boyd S, Pereira M, Lo J . Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015; 6(39):42008-18. PMC: 4747205. DOI: 10.18632/oncotarget.5788. View

Thomas N, Busam K, From L, Kricker A, Armstrong B, Anton-Culver H . Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol. 2013; 31(33):4252-9. PMC: 3821014. DOI: 10.1200/JCO.2013.51.3002. View

Wagle N, Van Allen E, Treacy D, Frederick D, Cooper Z, Taylor-Weiner A . MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2013; 4(1):61-8. PMC: 3947296. DOI: 10.1158/2159-8290.CD-13-0631. View

Johnson D, Menzies A, Zimmer L, Eroglu Z, Ye F, Zhao S . Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer. 2015; 51(18):2792-9. PMC: 4666799. DOI: 10.1016/j.ejca.2015.08.022. View

Weber J, Gibney G, Sullivan R, Sosman J, Slingluff Jr C, Lawrence D . Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016; 17(7):943-955. PMC: 5474305. DOI: 10.1016/S1470-2045(16)30126-7. View

Naoki K, Chen T, Richards W, Sugarbaker D, Meyerson M . Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res. 2002; 62(23):7001-3. View

10.

Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski T, Daud A . Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014; 15(9):954-65. DOI: 10.1016/S1470-2045(14)70301-8. View

11.

Kwong L, Costello J, Liu H, Jiang S, Helms T, Langsdorf A . Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012; 18(10):1503-10. PMC: 3777533. DOI: 10.1038/nm.2941. View

12.

Dummer R, Goldinger S, Turtschi C, Eggmann N, Michielin O, Mitchell L . Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer. 2013; 50(3):611-21. DOI: 10.1016/j.ejca.2013.11.002. View

13.

Atefi M, Von Euw E, Attar N, Ng C, Chu C, Guo D . Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One. 2011; 6(12):e28973. PMC: 3237573. DOI: 10.1371/journal.pone.0028973. View

14.

Kim H, Frederick D, Levesque M, Cooper Z, Feng Y, Krepler C . Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. Cell Rep. 2015; 11(9):1458-73. PMC: 4681438. DOI: 10.1016/j.celrep.2015.04.049. View

15.

Sen B, Peng S, Tang X, Erickson H, Galindo H, Mazumdar T . Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med. 2012; 4(136):136ra70. PMC: 3836384. DOI: 10.1126/scitranslmed.3003513. View

16.

Flaherty K, Robert C, Hersey P, Nathan P, Garbe C, Milhem M . Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012; 367(2):107-14. DOI: 10.1056/NEJMoa1203421. View

17.

Carvajal R, Antonescu C, Wolchok J, Chapman P, Roman R, Teitcher J . KIT as a therapeutic target in metastatic melanoma. JAMA. 2011; 305(22):2327-34. PMC: 3986039. DOI: 10.1001/jama.2011.746. View

18.

Spranger S, Bao R, Gajewski T . Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015; 523(7559):231-5. DOI: 10.1038/nature14404. View

19.

Dranoff G . GM-CSF-based cancer vaccines. Immunol Rev. 2002; 188:147-54. DOI: 10.1034/j.1600-065x.2002.18813.x. View

20.

Long G, Trefzer U, Davies M, Kefford R, Ascierto P, Chapman P . Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13(11):1087-95. DOI: 10.1016/S1470-2045(12)70431-X. View